Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)

Comments Delivered During Presentation at RHK Capital 2017 Disruptive Growth & Healthcare Conference at 10:45 a.m. ET Today FRAMINGHAM, MA ARTH, (Marketwired Feb 16, 2017)  Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH), developer of innovative materials as hemostatic and wound care devices, provided a corporate update during a live webcast this morning at 10:45 a.m. ET at the RHK Capital 2017 Disruptive Growth & Healthcare Conference in New York City. Replays of the live webcast can
http://bit.ly/2lofHTZ